Antiparticles have the same mass as particles of ordinary matter, but opposite charges, lepton and baryon numbers.
The work is a result of over 20 years of research by the antimatter community at CERN (European Organisation for Nuclear Research) in Switzerland.
"Using a laser to observe a transition in antihydrogen and comparing it to hydrogen to see if they obey the same laws of physics has always been a key goal of antimatter research," said Jeffrey Hangst, Spokesperson of the ALPHA collaboration, a unique experiment at CERN's Antiproton Decelerator facility.
Trapping antihydrogen atoms allows them to be studied using lasers or other radiation sources.
With its single proton and single electron, hydrogen is the most abundant and well-understood atom in the universe.
Its spectrum has been measured to very high precision. Antihydrogen atoms, on the other hand are poorly understood.
Since the universe appears to consist entirely of matter, the constituents of antihydrogen atoms - antiprotons and positrons - have to be produced and assembled into atoms before the antihydrogen spectrum can be measured.
ALPHA result is the first observation of a spectral line in an antihydrogen atom, allowing the light spectrum of matter and antimatter to be compared for the first time.
Within experimental limits, the result shows no difference compared to the equivalent spectral line in hydrogen.
This is consistent with the Standard Model of particle physics, which best describes particles and the forces at work between them and predicts that hydrogen and antihydrogen should have identical spectroscopic characteristics.
Antihydrogen is made by mixing plasmas of about 90,000 antiprotons from the Antiproton Decelerator with positrons, resulting in the production of about 25,000 antihydrogen atoms per attempt. They can be trapped if they are moving slowly enough when they are created.
Using a new technique in which the collaboration stacks anti-atoms resulting from two successive mixing cycles, it is possible to trap on average 14 anti-atoms per trial, compared to just 1.2 with earlier methods.
The study was published in the journal Nature.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
